PT -期刊文章盟Pietro Iaffaldano AU -玛尔塔西蒙盟罗莎吉玛Viterbo AU -卢西亚Margari盟-玛丽亚阿马托盟-玛丽亚Trojano TI -计算机辅助康复的关注在小儿发病多发性硬化和注意缺陷多动障碍(S9.003) DP - 2016年4月05 TA -神经病学PG - S9.003 VI - 86 IP - 16补充4099 - //www.ez-admanager.com/content/86/16_Supplement/S9.003.short 4100 - //www.ez-admanager.com/content/86/16_Supplement/S9.00首页3.full所以Neurology2016 4月05;86 AB -背景:认知康复的效果在儿童发病多发性硬化症(盐)一直没有调查到目前为止,而这仍然是有争议的在注意缺陷多动障碍(ADHD)。摘要目的:探讨家庭电脑培训项目的效果在酸盐和多动症注意力障碍。方法:在研究包容、盐和多动症经历了一个广泛的神经心理学评估(NP),包括Symbol-Digit-Modalities-Test (SDMT)、伦敦塔(TOL) Trial-Making-Test-A (TMT-A) Spatial-Recall测试(脱离)和SPART-delayed (SPART-D)。失败的患者≥2测试的关注被随机分配到特定的或非特异性电脑培训(ST,望远镜)组成的一小时的会议,每周两次为三个月。完成后NP是重复的训练。重复测量方差分析进行比较的性能在每个认知测试的病人接受圣或望远镜。结果:16(9雌性;平均数±标准差年龄:15.8±1.7年)酸盐和20(2女性;年龄:11.2±2.5年)多动症患者登记。 At baseline, in each disease group no differences were found between the 2 treatment arms regarding sex, age, and NP performances. POMS treated with ST, but not those treated with nST, significantly improved their performances on SDMT (ST 24.5±4.6 vs 46.3±6.7;nST 20.5±3.6 vs 20.8±4.1;p<0.0001), TOL (ST 15.8±5.4 vs 30.4±2.5; nST 15.6±6.6 vs 13.8±2.0;p<0.0001), TMT-A (ST 39.4±11.5 vs 31.8±6.6;nST 34.6±9.8 vs 43.8±10.2;p=0.012), SPART (ST 19.3±4.4 vs 25.5±1.7;nST 22.3±2.0 vs 23.1±1.9;p=0.004) and SPART-D (ST 6.8±1.0 vs 8.1±0.8;nST 7.0±1.4 vs 6.1±0.8;p=0.004). In the ADHD group, ST-treated, but not nST-treated, patients showed an improvement for SDMT (ST 17.1±5.5 vs 35.8±7.2;nST 17.4±11.1 vs 22.1±11.4;p=0.004) and SPART-D (ST 6.0±2.2 vs 7.7±1.8;nST 6.9±2.3 vs 6.6±1.2;p=0.04). Conclusions: our data show that an attention ST may improve attention dysfunction in both POMS and ADHD. Moreover it seems to have also a beneficial transfer effect on executive functioning, cognitive speed and visuo-spatial memory in POMS, but not in ADHHD.Disclosure: Dr. Iaffaldano has received personal compensation for activities with Biogen Idec and Bayer as a scientific advisory board member and has received funding for travel and/or speaker honoraria from Genzyme, Biogen Idec, Teva, and Novartis. Dr. Simone has nothing to disclose. Dr. Viterbo has nothing to disclose. Dr. Margari has nothing to disclose. Dr. Amato has received personal compensation for activities with Biogen Idec, Merk Serono, Bayer, Novartis, Teva, Sanofi, Genzyme, Almirall. Dr. Trojano has received research support from Biogen Ide., Merck-Serono and Novartis Pharmaceuticals.Sunday, April 17 2016, 6:30 am-7:15 am